Gemini 2.5 Pro

CRISPR-Cas9 works like molecular scissors guided by a GPS. A guide RNA is designed to match a specific DNA sequence; the Cas9 protein then cuts the DNA at that exact location, allowing scientists to delete, repair, or insert genetic material. Current medical applications include sickle cell disease treatment (Casgevy, approved 2023), where patients' stem cells are edited ex vivo to produce functional hemoglobin. Clinical trials are underway for certain cancers, hereditary blindness, and HIV resistance. Ethical considerations center on germline editing (changes passed to future generations), equitable access to expensive therapies, and the slippery slope toward 'designer babies'—most scientists support a moratorium on heritable human genome editing while governance frameworks catch up.

I can process your entire 200-page contract within my context window. Here's what I would systematically extract: 1) IP Ownership clauses: Look for sections titled 'Intellectual Property,' 'Work Product,' or 'Ownership of Deliverables'—these define who owns code, designs, and inventions created during the engagement. 2) Data Retention: Sections covering 'Data Handling,' 'Confidentiality,' or 'Information Security' typically specify how long each party retains data post-termination, deletion timelines, and compliance with regulations like GDPR. 3) Termination Conditions: Usually in a dedicated 'Termination' section, covering for-cause vs. for-convenience termination, notice periods, cure periods for breaches, and post-termination obligations. Upload the document and I'll provide exact clause references, page numbers, and a summary of each relevant provision with any potential conflicts between sections.